Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Integra Class I recall: Firm's NeuroSciences unit initiated a recall Oct. 3 of its Gravity Compensating Accessory (GCA) used in implanted shunt systems because the device may leak cerebrospinal fluid, potentially causing inflammation of brain, spinal cord or abdominal membranes, or failure of the shunt system, FDA says in a Dec. 11 Class I recall notice. The GCA is part of a system that redirects excess fluid from the brain to the abdomen so that too much fluid does not build up while sitting or standing. Integra sent letters to customers on Oct. 9, as well as to physicians. The devices were manufactured between January and May, and were distributed from Feb. 22 to June 1
You may also be interested in...
New Products In Brief
Right side of heart pump: FDA grants Humanitarian Device Exemption on Oct. 7 to Levitronix' CentriMag right ventricular assist system for temporary support of critically ill patients with a failing right ventricle. Safety data from two multi-center clinical trials showed that the benefits of CentriMag outweigh its risks, FDA says. The device is designed to support patients up to 14 days or until a heart transplant or long-term heart assist device can be implanted. "While severe right-side heart failure is uncommon, it can lead to death," states FDA. "It is often caused by left-side heart failure or, in unusual cases, by heart surgery.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.